Sign inCreate account

Report workspace

Add to folder
NCT01066546TERMINATEDanonymous

An Open-Label Extension To The B1451006 Protocol To Evaluate The Safety And Efficacy Of Dimebon (Latrepirdine, PF-01913539) In Subjects With Moderate-To-Severe Alzheimer's Disease

Sponsor

Source record

Pfizer

Phase

Source record

Phase 3

Modality

AI-normalized

small molecule

Target

AI-normalized

Dimebon (Latrepirdine) - Mechanism of action not fully elucidated; previously hypothesized to modulate mitochondrial function and exert neuroprotective effects.

Indication / condition

AI-normalized

Alzheimer's Disease

Intervention

Source record

Dimebon tablet for oral administration

Source & freshness

Source record

NCT ID

NCT01066546

Original source

ClinicalTrials.gov

Source last updated

Oct 02, 2012

Ingested at

Jun 18, 2026

Internal sync

Jun 18, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT01066546

Title

An Open-Label Extension To The B1451006 Protocol To Evaluate The Safety And Efficacy Of Dimebon (Latrepirdine, PF-01913539) In Subjects With Moderate-To-Severe Alzheimer's Disease

Sponsor

Pfizer

Status

TERMINATED

Phase

Phase 3

Condition raw

Alzheimer's Disease

Condition normalized

Alzheimer's Disease

Modality raw

small molecule

Modality normalized

small molecule

Target raw

Dimebon (Latrepirdine) - Mechanism of action not fully elucidated; previously hypothesized to modulate mitochondrial function and exert neuroprotective effects.

Target normalized

Dimebon (Latrepirdine) - Mechanism of action not fully elucidated; previously hypothesized to modulate mitochondrial function and exert neuroprotective effects.

Interventions

Dimebon tablet for oral administration

Public preview

Source record

The clinical trial for Dimebon in moderate-to-severe Alzheimer's disease was terminated due to a lack of demonstrated efficacy in prior studies, specifically the DIM14 (CONNECTION) Study. This raises significant concerns regarding the asset's viability in a competitive market where effective treatments for Alzheimer's are in high demand. The termination may impact Pfizer's strategic positioning in the neurodegenerative disease space, as the company may need to pivot resources towards more promising candidates. Additionally, the collaboration with Medivation, Inc. may require reassessment in light of this outcome. The Alzheimer's market remains lucrative, but the failure of Dimebon could hinder Pfizer's market share and investor confidence.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

An Open-Label Extension To The B1451006 Protocol To Evaluate The Safety And Efficacy Of Dimebon (Latrepirdine, PF-01913539) In Subjects With Moderate-To-Severe Alzheimer's Disease

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 18, 2026

NCT ID

NCT01066546

Status

TERMINATED

Phase

Phase 3

Sponsor

Pfizer

Executive brief

Investment-Ready Snapshot

The clinical trial for Dimebon in moderate-to-severe Alzheimer's disease was terminated due to a lack of demonstrated efficacy in prior studies, specifically the DIM14 (CONNECTION) Study. This raises significant concerns regarding the asset's viability in a competitive market where effective treatments for Alzheimer's are in high demand. The termination may impact Pfizer's strategic positioning in the neurodegenerative disease space, as the company may need to pivot resources towards more promising candidates. Additionally, the collaboration with Medivation, Inc. may require reassessment in light of this outcome. The Alzheimer's market remains lucrative, but the failure of Dimebon could hinder Pfizer's market share and investor confidence.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedOct 02, 2012
Internal syncJun 18, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT01066546

Indication

Alzheimer's Disease

Modality

small molecule

Target

Dimebon (Latrepirdine) - Mechanism of action not fully elucidated; previously hypothesized to modulate mitochondrial function and exert neuroprotective effects.

Intervention

Dimebon tablet for oral administration

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.